Eli Lilly’s New Pill Loses Market Lead to Novo Nordisk’s...
Key Takeaways Eli Lilly’s orforglipron and Novo Nordisk’s oral semaglutide are locked in a competitive battle for supremacy in the lucrative oral weight-loss drug market. Clinical trial data shows nuanced...